Navigation Links
Avicena Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Date:12/3/2007

Selected Therapy Can Advance to Phase III Clinical Trial

PALO ALTO, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Avicena Group, Inc. (OTC Bulletin Board: AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases, today announced positive Phase II data for a combination trial involving AL-08, the Company's second generation proprietary drug candidate for the treatment of ALS. The purpose of the trial was to determine which of two compounds used in combination with AL-08 would yield the most favorable results, so that the Company could proceed to a Phase III trial. Results were presented by Paul H. Gordon, MD of Columbia University in a presentation titled "Combination Drug Selection Trial in Amyotrophic Lateral Sclerosis" at the 18th International Symposium on ALS/MND in Toronto, Canada on December 3, 2007. This study was funded by the ALS Association, Ride for Life, and the Russ Bowen and Spina Family Foundations.

The Phase II trial evaluated the neuroprotective capacity of two combinations, AL-08 and minocycline versus AL-08 with celecoxib, using group sequential design and a natural history control group for a futility analysis. The primary objective of the trial was selection of a treatment based on which drug combination appeared to slow deterioration in the ALS- Functional Score. Results showed that patients taking the AL-08/celecoxib combination showed a smaller mean decline in ALS- Functional Score compared to those taking the AL- 08/minocycline combination. Results also showed that the AL-08/celecoxib combination was non-futile compared to historical controls, and merits further evaluation. The trial was concluded ahead of schedule after the first pool of patients met the selection criteria.

"We are encouraged that the AL-08/celecoxib combination showed less of a decline in ALS-Functional Score compared to AL-08 and minocycline and historical control. Since the dif
'/>"/>

SOURCE Avicena Group, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
2. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
(Date:1/14/2014)... 14, 2014 Animal Emergency Critical Care, a LifeCentre partner practice, ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a ... Dr. Cole Taylor , are avid scuba divers. "As altitude ...
(Date:1/14/2014)... PORT WASHINGTON, New York , January 14, ... the leading provider of Closed System Transfer Devices (CSTD) for hazardous drugs, ... sales growth for the fourth straight year.   ... of exposure for pharmacy technicians, pharmacists, nurses and ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2Equashield's Sales Grow by 60% in 2013 2
... , NEW BRUNSWICK, N.J., Nov. 12 Senesco ... SNT ) announced today that Catherine Taylor, ... presenting pre-clinical stability and biological activity data on ... 2009 American Association for Cancer Research (AACR)-National Cancer ...
... Thoratec Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said today that it will ... HeartMate II Destination Therapy clinical trial that will be ... the American Heart Association(AHA) Scientific Sessions 2009. , The ...
Cached Medicine Technology:Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 3
(Date:7/10/2014)... the "Mississippi baby" an infant seemingly cured of HIV ... remission of HIV infection in The New England Journal ... after more than two years of not taking antiretroviral therapy ... and researchers involved in the case. , "Certainly, ... child, the medical staff involved in the child,s care, and ...
(Date:7/10/2014)... research at the University of Huddersfield could help to ... emulsion-based food products such as butter, mayonnaise, yoghurt ... gain an international profile for her work. , Katerina ... at the University and now she has embarked on ... Dr Vassilis Kontogiorgos, she is investigating the potential of ...
(Date:7/10/2014)... with localized prostate cancer were more likely to ... less effective treatments and survived for shorter times ... a UCLA study has found. , The negative ... such as bias against the mentally ill, depression,s ... lack of investment in his general health and ...
(Date:7/9/2014)... 2014) If you think winning is one of the ... again: Winning along with other mental bonuses ranked near the ... into one of 11 big fun factors, according to a ... important when it comes to the "fun" factor, very little ... goes into this elusive conceptuntil now. , The results of ...
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
Breaking Medicine News(10 mins):Health News:'Mississippi Baby' now has detectable HIV, researchers find 2Health News:'Mississippi Baby' now has detectable HIV, researchers find 3Health News:World interest in research work on the benefits of the Okra plant 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2
... 25, 2010 (Toronto) A new study from The Centre ... accounts for 43% of all cigarettes consumed by Ontario high ... The study, published in the current edition of Tobacco ... and found that of high school daily smokers, 50% smoked ...
... Amanda Gardner HealthDay Reporter , FRIDAY, Oct. 22 ... Staphylococcus aureus , or MRSA, a common bacterial infection acquired ... presented at the annual meeting of the Infectious Diseases Society ... of the people it infected within 30 days, the study ...
... DETROIT Patients admitted to the hospital for the ... a first line of defense with the potent antibiotic ... according to a Henry Ford Hospital study. For ... whether vancomycin or so-called B-lactam antibiotics like penicillin or ...
... Reporter , FRIDAY, Oct. 22 (HealthDay News) -- You might have seen ... an Iraq War vet with severe burns across much of his body ... his injuries. Martinez, 27, earned the right to play that role ... month into his first Iraq deployment as a real-life Army soldier, his ...
... School of Medicine, led by Lucila Ohno-Machado, MD, PhD, ... Department of Medicine, have received two federal grants totaling ... gather, analyze, use and share vast, ever-increasing amounts of ... over five years will create a national center for ...
... new cancer research being released at the American Society for ... 31 through November 4, 2010, in San Diego. For ... Napoli at nicolen@astro.org or Beth Bukata at ... 1:00 p.m. Eastern time. Adding radiation to hormone ...
Cached Medicine News:Health News:Contraband cigarettes main source of supply for Ontario youth 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 2Health News:MRSA Strain With Outbreak Potential Among Reports at Disease Conference 3Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 2Health News:Iraq War Vet, Daytime TV Star Turns Scars Into Inspiration 3Health News:UC San Diego receives 2 major biomedical informatics grants 2Health News:UC San Diego receives 2 major biomedical informatics grants 3Health News:UC San Diego receives 2 major biomedical informatics grants 4Health News:Practice-changing studies on how oncologists treat cancer to be presented at ASTRO Annual Meeting 2
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 150o....
Angled blade and flat serrated handle with polished finish. Blade: 1 mm x 10 mm....
Angled tip with gently curved blade. Short hexagonal handle with polished finish. 0.5 mm x 15 mm tip....
0.5 mm short 90 degree angled tip with black ebonized shaft. Titanium handle with position reference indicator. Shaft length 52 mm, handle length 100 mm....
Medicine Products: